Over the past 12 months, $SGMO generated 18 mentions from 2 distinct FinTwit voices, with @adamfeuerstein accounting for 17 of those mentions and @investmentguru_ contributing 1. Discussion of Sangamo Therapeutics began on September 11, 2025, and continued through June 23, 2026. The biotech sector was the primary category for commentary on this ticker.

The most recent activity centers on the company's financial trajectory, with @adamfeuerstein posting that "$SGMO ends with bankruptcy sale of its assets. Lilly and Astellas stalking horse bidders" on June 23, 2026. Earlier posts from the same voice in April 2026 expressed skepticism about the company's situation.